Answers are grounded in this paper and cite their sources.
Molecular profiling is essential for therapeutic decision-making in metastatic castration-resistant prostate cancer (mCRPC), but implementation is limited by tissue availability, bone-predominant disease, tumor heterogeneity and organizational barriers. This conference report summarizes a multidisciplinary educational meeting held in Naples, Italy, on 12 May 2026. The program combined presentations, moderated multidisciplinary discussions and two exploratory audience polls addressing nine questions. Survey results were summarized descriptively to contextualize the discussion. Molecular profiling was viewed as an integrated diagnostic pathway rather than an isolated laboratory test. Successful implementation requires timely planning, involvement of interventional radiologists in the multidisciplinary selection among nodal, visceral, osseous and other metastatic biopsy targets, optimized tissue acquisition and processing, early pathological assessment of specimen adequacy and coordinated interpretation of molecular findings. Archival tissue, newly acquired metastatic tissue, liquid biopsy and re-biopsy were considered complementary strategies to optimize profiling according to disease characteristics, specimen availability, prior results and clinical needs. Non-informative results should prompt reassessment and consideration of an alternative sampling strategy, consistent with diagnostic persistence. Implementation depends on multidisciplinary collaboration and adaptable pathways addressing access, geographic equity and resource sustainability. This evidence-informed framework aims to support harmonization of molecular profiling pathways in mCRPC without yet constituting recommendations or formal consensus.
No takes yet. Share an insight, caveat, or question.
Bracarda et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: